Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline
Business Wire•23/10/2026•09:00 ET
0
Key Highlights
- ➤Pathos AI raises $237 million in Series E financing at approximately $3 billion post-money valuation
- ➤Bristol Myers Squibb leads Pathos AI’s Series E financing alongside existing investors
- ➤Pathos AI expands its clinical-stage oncology pipeline to four active assets
- ➤JSKN016 advances toward registrational studies as a first-in-class TROP2/HER3 bispecific ADC
- ➤Proceeds will scale Foundry and advance pocenbrodib, AZD4241, and DO-2 clinical programs
Expert Statements
Iker Huerga, CEO of Pathos AI
“We are building a platform to systematically improve the probability of success in drug development”
Iker Huerga, CEO of Pathos AI
“Foundry has fundamentally accelerated our ability to identify highly promising clinical assets and integrate them into our pipeline. This capital allows us to rapidly scale our AI engine while actively steering our current programs toward key clinical milestones, ensuring we deliver the right therapies to the right patient populations.”
Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline
Funding follows rapid portfolio expansion and will power the initiation of a registrational study for AI-identified asset JSKN016
Get started
Create a free account to read the full story.